Análise de crescimento do capim Coastcross-1 sob adubação nitrogenada em duas idades de rebrotação

Avaliaram-se os índices de crescimento do capim Coastcross-1 sob cinco doses de nitrogênio (0, 100, 200, 300 e 400 kg/ha.ano) e duas idades de rebrotação (28 e 42 dias). As doses de nitrogênio foram arranjadas em esquema fatorial 5 × 2, em blocos ao acaso, com três repetições. A adubação nitrogenada foi parcelada em três aplicações, realizadas logo após os cortes. Maiores valores de relação folha/colmo e razão de peso foliar foram obtidos aos 28 dias, em comparação aos 42 dias de rebrotação. Houve redução linear na relação folha/colmo com a adubação nitrogenada (de 1,6 para 1,0 nas doses de 0 e 133 kg/ha.corte de N). Por outro lado, a adubação nitrogenada aumentou linearmente a área foliar específica do capim Coastcross-1 aos 28 dias de rebrotação (de 10,3 a 20,8 m²/kg com o incremento de 0 a 133 kg/ha.corte de N), resultando em elevação da sua razão de área foliar. Na ausência de nitrogênio, a área foliar específica foi maior aos 42 dias (14,3 m²/kg) em relação aos 28 dias de rebrotação (8,6 m²/kg). A idade de rebrotação e a adubação nitrogenada modificam o padrão de acúmulo de forragem e as características do pasto de capim Coastcross-1. Durante a estação de maior crescimento, o pasto de capim Coastcross-1 adubado com maior dose de nitrogênio deve ser manejado com menor idade de rebrotação (28 dias).The Coastcross-1 growth index in relation to five nitrogen doses (0, 100, 200, 300 and 400 kg/ha.year) and two regrowth ages (28 and 42 days) were evaluated. Nitrogen doses were arranged in a 5 × 2 factorial scheme in a randomized complete block design with three repetitions. Nitrogen fertilization was performed in three applications right after the forage harvesting. Higher values for leaf/stem and leaf weight ratio were observed at 28-d regrowth, in comparison with the 42 days of regrowth. Linear reduction of leaf/stem ratio from 1.6 to 1.0 at 0 and 133 kg N/ha.harvest, respectively was observed. The specific leaf area of bermudagrass at 28-d regrowth resulted in increased leaf area ratio (from 10.3 to 20.8 m²/kg with the increase of 0 to 133 kg N/ha. Harvest). At the absence of N treatment, specific leaf rate was higher at 42-d (14.3 m²/kg) in relation to the 28-d of regrowth (8.6 m²/kg). Regrowth age and nitrogen fertilization modify the pattern of forage accumulation and the characteristics of Coastcross-1 pasture. During the summer, the Coastcross-1 grass pasture fertilized with the highest N-dose should be managed at a younger regrowth age (28-d)

Somaclones em batata identificados pelos descritores mínimos de broto

Este estudo objetivou verificar a estabilidade fenotípica das cultivares de batata 'Asterix' e 'Macaca', avaliar o efeito do tipo de explante (organogênese direta e indireta) e do tempo de subcultivo (12 e 70 meses) em meio nutritivo MS sobre a ocorrência de somaclones nas duas cultivares na produção de batata semente, mediante o emprego de sete descritores mínimos de broto. Em 'Asterix' e 'Macaca' ocorreram somaclones em quatro dos sete descritores, contudo, apenas no formato e pubescência da base do broto houve variação, simultaneamente, em ambas. Os dois genótipos são suscetíveis à ocorrência de variação somaclonal. Registrou-se somaclonesnos dois tempos de subcultivo nas duas cultivares. Diferente do amplamente registrado, identificaram-se somaclones em segmentos apicais caulinares e nodais originados de organogênese direta em 'Asterix' e 'Macaca'

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings: Global DALYs increased from 2·63 billion (95% UI 2·44–2·85) in 2010 to 2·88 billion (2·64–3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7–17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8–6·3) in 2020 and 7·2% (4·7–10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0–234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7–198·3]), neonatal disorders (186·3 million [162·3–214·9]), and stroke (160·4 million [148·0–171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3–51·7) and for diarrhoeal diseases decreased by 47·0% (39·9–52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0–19·8]), depressive disorders (16·4% [11·9–21·3]), and diabetes (14·0% [10·0–17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7–27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6–63·6) in 2010 to 62·2 years (59·4–64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6–2·9) between 2019 and 2021. Interpretation: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Funding: Bill & Melinda Gates Foundation